Bosutinib is a tyrosine kinase inhibitor approved by the FDA and EMA in 2012-2013 for the treatment of chronic myelogenous leukemia. It suppresses migration and invasion of breast cancer cells by inhibiting signaling pathways controlling tumor cell motility and invasion. Bosutinib comes in 100 mg and 500 mg doses and works by blocking certain tyrosine kinases.

1. Bosutinib

2. Bosutinib received US FDA and E
U European Medicines Agency a
pproval on September 4, 2012 a
nd 27 March 2013 respectively.
bosutinib is a tyrosine kinase inh
ibitor for use in the treatment of
chronic myelogenous leukemia (
CML).
Bosutinib suppresses migration a
nd invasion of human breast can
cer cells as it inhibits signaling p
athways involved in controlling t
umor cell motility and invasion

3. Bosutinib forms:
• Bosulif 100 mg.
• Bosulif 500 mg.

4. bosutinib structure:

5. Mechanism of action :